N-n-undecyl-n-propylamine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-n-undecyl-n-propylamine
• 英文别名: N-propylundecan-1-amine
• 化学式: C₁₄H₃₁N
• 分子量: 213.407
• InChiKey: QRPSACOFSBZHOT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  15
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS
  申请人：Giranda Vincent L.

  公开号：US20070259937A1

  公开（公告）日：2007-11-08

  The present invention relates to 1H-benzimidazole-4-carboxamides of formula (I), their preparation, and their use as inhibitors of the enzyme poly(ADP-ribose)polymerase for the preparation of drugs.

  本发明涉及式(I)的1H-苯并咪唑-4-甲酰胺、其制备以及作为聚(ADP-核糖)聚合酶的抑制剂以制备药物的用途。
• PEPTIDES FOR THE TREATMENT OF CANCER
  申请人：H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.

  公开号：US20150071918A1

  公开（公告）日：2015-03-12

  The invention relates to novel cyclic compounds (cyclic peptides), linkers useful as beta-turn promoters in cyclic peptides, and methods for treatment of malignant cells in vitro or in vivo using one or more linear and cyclic peptides. The peptides can act as integrin interaction inhibitors and may be used in the treatment of cancers as monotherapies or in combination with other anti-cancer agents, such as proteasome inhibitors, inhibitors of autophagy, alkylating agents, MEK inhibitors, FAK/PYK2 inhibitors, and EGFR inhibitors. The invention further concerns a method of predicting the binding of a cyclic or linear HYD1 peptide to a cancer cell by assessing overexpression of biomarkers such as CD44, VLA-4 integrin, basigin, CD138 (syndecan 1), NCAM, ICAM1, ICAM3, and CD59. The invention further concerns a method of detecting one or more members of a complex comprising CD44, VLA-4 integrin, basigin, CD138 (syndecan 1), NCAM, ICAM1, ICAM3, and CD59, using a linear or cyclic HYD1 peptide bearing a detectable moiety.

  本发明涉及新型环状化合物（环状肽）、在环状肽中作为β-转角促进剂有用的连接剂，以及使用一种或多种线性和环状肽治疗体外或体内恶性细胞的方法。这些肽可以作为整合素相互作用抑制剂，并可用于单独治疗或与其他抗癌药物（如蛋白酶体抑制剂、自噬抑制剂、烷化剂、MEK抑制剂、FAK/PYK2抑制剂和EGFR抑制剂）联合治疗癌症。本发明进一步涉及通过评估过表达的生物标志物（如CD44、VLA-4整合素、basigin、CD138（syndecan 1）、NCAM、ICAM1、ICAM3和CD59）来预测环状或线性HYD1肽与癌细胞结合的方法。本发明还涉及一种使用带有可检测基团的线性或环状HYD1肽检测CD44、VLA-4整合素、basigin、CD138（syndecan 1）、NCAM、ICAM1、ICAM3和CD59复合物中一种或多种成员的方法。
• PHOTOACOUSTIC IMAGE GENERATING DEVICE AND INSERTION OBJECT
  申请人：Fujifilm Corporation

  公开号：EP2944264A1

  公开（公告）日：2015-11-18

  Even when an insertion object is inserted to a deep position of a subject or even when the insertion object is inserted into the subject at an angle close to a right angle, it is possible to confirm the position of the insertion object in a photoacoustic image. The insertion object is, for example, a hollow puncture needle 15 that includes an opening at a tip thereof. The puncture needle 15 includes a light guide member 152 that guides light emitted from a first light source to the vicinity of the opening, and a light emitting portion 153 that is provided in the vicinity of the opening and emits the light guided by the light guide member 152. First photoacoustic waves, which are caused by the light emitted from the light emitting portion 153, are generated in the puncture needle 15. After the puncture needle is inserted into the subject, the first photoacoustic waves are detected and a first photoacoustic image is generated on the basis of the first photoacoustic waves.

  即使将插入物体插入被摄体的深部位置，或者将插入物体以接近直角的角度插入被摄体，也可以在光声图像中确认插入物体的位置。例如，插入物体是一个空心穿刺针 15，其顶端有一个开口。穿刺针 15 包括一个导光部件 152，用于将第一光源发出的光引导到开口附近；以及一个发光部分 153，设置在开口附近并发射由导光部件 152 引导的光。由发光部分 153 发出的光引起的第一光声波在穿刺针 15 中产生。将穿刺针插入受试者体内后，检测第一光声波，并根据第一光声波生成第一光声图像。
• PRESERVATION OF RNA IN A BIOLOGICAL SAMPLE
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP1623010A2

  公开（公告）日：2006-02-08
• EP1623010A4
  申请人：——

  公开号：EP1623010A4

  公开（公告）日：2007-12-26